Background. Prospective data on the risks of cervical precancer associated with specifi human papillomavirus (HPV) genotypes are limited.
much stronger viral carcinogen than any other type [10] [11] [12] . HPV-16 persists longer than most other HPV types [4] and, therefore, has higher prevalence. When it persists for 11 or 2 years, HPV-16 is more likely to cause cervical precancer and cancer than the other potentially carcinogenic types [4] . Globally, HPV-16 causes approximately one-half of cervical cancer cases [6] [7] [8] [9] .
It has been difficul to assess the carcinogenicity of HPV types other than HPV-16. The other types are less common among the general population and among women with cervical cancer or precancer outcomes, thus limiting the precision of risk estimates. Determining risk estimates for precancer and cancer when multiple HPV infections are detected is particularly difficul when HPV-16 is one of the coinfecting types and, therefore, dominates the risk.
Addressing these concerns requires a very large study population of infected women with complete typing for the full range of HPV types and a large number of rigorously define disease outcomes. No currently established study population is big enough to evaluate precisely the risk posed by the least common and weakest of the carcinogenic HPV types. However, in one of the biggest efforts to date, we present data here from the Atypical Squamous Cells of Undetermined Significanc (ASCUS)/Low-Grade Squamous Intraepithelial Lesions (LSIL) Triage Study (ALTS) [13] , in which we have characterized the 2-year cumulative risk of cervical intraepithelial neoplasia (CIN) grade 2 or more severe (уCIN2) and of grade 3 or more severe (уCIN3) for 14 individual carcinogenic HPV types and 24 noncarcinogenic or uncharacterized HPV types.
SUBJECTS, MATERIALS, AND METHODS
Study design and population. ALTS was a randomized trial comparing the following 3 management strategies for 5060 women with ASCUS ( ) or LSIL ( ) [13] : (1) n p 3488 n p 1572 immediate colposcopy (referral to colposcopy regardless of enrollment test results); (2) HPV triage (referral to colposcopy if the enrollment HPV testing result was either positive by Hybrid Capture 2 [Digene Corporation, Gaithersburg, MD] or missing or if the enrollment cytological diagnosis was high-grade squamous intraepithelial lesion [HSIL] ); or (3) conservative management (referral to colposcopy at enrollment if the cytological diagnosis was HSIL). At enrollment, all women received a pelvic examination with collection of 2 cervical specimens; the firs specimen was collected in PreservCyt for ThinPrep cytological analysis (Cytyc Corporation, Boxborough, MA), and the second specimen was collected in specimen transport medium (STM; Digene). Women in all 3 arms of the study were reevaluated by cytological analysis every 6 months for 2 years of follow-up and were sent for a colposcopy if the cytological diagnosis was HSIL. An exit examination with colposcopy was scheduled for all women, regardless of study arm or prior procedures, at the completion of the follow-up. We refer readers elsewhere for details on randomization, examination procedures, patient management, and laboratory and pathological methods [13] [14] [15] [16] [17] . The National Cancer Institute and local institutional review boards approved the study, and all participants provided written, informed consent.
HPV DNA testing. HPV typing was performed using an L1-based polymerase chain reaction (PCR) assay that employs a primer set designated PGMY09/11 and was performed on the STM specimen [18] . Amplimers were subjected to reverse-line blot hybridization for detection of 27 individual HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, (51) (52) (53) (54) (55) (56) (57) (58) (59) 66, 68, 73 [PAP238a], 82 [W13b], 83 [PAP291] , and 84 [PAP155]) [19] . We also tested for an additional 11 HPV types (61, 62, 64, 67, [69] [70] [71] [72] 81, 82v [IS39], and 89 [CP6108] ) in approximately onehalf of the specimens (58%) at enrollment and in all specimens collected at the follow-up visits [20] .
Pathological analysis and treatment. Clinical management was based on clinical center pathologists' cytologic and histologic diagnoses. In addition, all referral smears, ThinPreps, and histology slides were sent to the Pathology Quality Control Group (PQCG), based at the Johns Hopkins Hospital, for review and secondary diagnoses. The outcomes of interest for these analyses were уCIN2 (which was based on the clinical center diagnosis, because it triggered treatment by loop electrical excision procedure) and уCIN3 (which was based on the PQCG diagnosis) as the preferred scientifi surrogate for cancer risk.
Statistical methods. Of the 5060 women enrolled in ALTS, 4915 (97.1%) had successful HPV testing of 27 HPV types at entry into the study. Ten women received 2 HPV PCR tests at study entry, and the results from both tests were combined for these analyses, such that types detected by either assay were included. A subset of 2833 women had successful testing for an additional 11 HPV types.
For purposes of these analyses, we considered HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , and 68 as primary carcinogenic types and HPV types 6, 11, 26, 40, 42, 53, 54, 55, 57, 61, 62, 64, 67, [69] [70] [71] [72] [73] 81, 82, 82v, 83, 84, and 89 (CP6108) as noncarcinogenic types. Women were assigned to an HPV risk group according to a priori established cervical cancer risk: positive for HPV-16, else positive for any carcinogenic HPV type and negative for HPV-16 (hereafter, "carcinogenic types without HPV-16"), else positive for any noncarcinogenic HPV type and negative for all carcinogenic types, else PCR negative.
Cumulative 2-year risks for уCIN2 and уCIN3 were computed by considering any diagnosis made at entry, during the 2 years of follow-up, or at exit from the study. Of the 4915 women, only the 3944 (80.2%) who completed the 24-month follow-up visit were included in these analyses. We computed HPV type-specifi risks of уCIN2 and уCIN3 for women who tested positive at entry for the specifi type only. We also computed risks for classes of HPV on the basis of their carcinogenic potential as described above.
In further analyses, we divided the study period into 2 intervals: (1) enrollment visit up to the 12-month visit (hereafter, "year 1 period") and (2) 12-month visit through the 24-month visit or exit from the study (hereafter, "year 2 period"). The HPV risk status for each interval was based on the presence of the HPV type in the highest HPV risk group during that interval. We then computed the risks of уCIN2 and уCIN3 during the year 2 period among women who had not received a diagnosis of or treatment for уCIN2 during the year 1 period. We restricted these analyses to the women in the immediate colposcopy and HPV triage study arms, because of the insensitive diagnosis of уCIN2 during the year 1 period in the conservative management arm [21] . Women without HPV testing for both time periods and without an exit colposcopy were excluded. The total number of women included in these analyses was 2122.
Confidenc intervals (CIs) were computed using exact pro-cedures, and comparisons of estimates of risk were tested for significanc using the Pearson x 2 statistic or the Cochran-Armitage test of trend, with an exact P value. SAS (version 9.1; SAS Institute) was used for all analyses.
RESULTS
The type-specifi HPV prevalence at study entry for this population of women with ASCUS and LSIL is shown in table 1. Overall, 68.4% of the women ( ) tested positive for at n p 3362 least 1 type of HPV. Of those women who were HPV positive, 43.7% were positive for only a single type, 28.0% were positive for 2 types, 15.4% were positive for 3 types, and 12.9% were positive for 4-12 types. For any given type, ∼20% occurred as a single-type HPV infection. The most common HPV types were, in descending order of prevalence, 16 (16.8%), 52 (9.4%), 51 (8.1%), 31 (7.1%), and 18 (6.6%). Table 1 also presents the cumulative 2-year risk for a clinical center diagnosis of уCIN2 and a PQCG diagnosis of уCIN3 by type of HPV detected at study entry for women with singletype HPV infections. The risk of уCIN2 or уCIN3 associated with HPV-16 was greater than that observed for any other HPV type. Among women who were infected only with HPV-16, the cumulative 2-year risk of уCIN2 was 50.6% (95% CI, 44.1%-57.2%), and the risk of уCIN3 was 39.1% (95% CI, 32.9%-45.7%).
Other known carcinogenic types had risks of уCIN2 and уCIN3 that were lower than those for HPV-16 but were generally higher than those for noncarcinogenic or uncharacterized types. Among women with single-type infections of a carcinogenic type other than 16 (18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) , the 2-year cumulative risk of уCIN2 ranged from 4.7% (for HPV-59) to 29.5% (for HPV-31). Overall, the risk of уCIN2 among women with a single carcinogenic type other than 16 was 18.8%. Women who were initially negative for HPV by PCR had a risk of 2.4% for уCIN3. Of these 38 PCR-negative women with уCIN3, 19 tested positive by use of a second cervical specimen and HPV test for carcinogenic HPV (Hybrid Capture 2; Digene Corporation). The risk of уCIN3 for the remaining 19 PCR-negative, Hybrid Capture 2-negative women was 1.4%.
The 2-year cumulative risk of уCIN2 and уCIN3 was greater for the HPV risk groups more strongly associated with cancer (table 2) . For example, the 2-year risk of уCIN2 for single-type HPV infections was 8.2% for noncarcinogenic types, 18.8% for carcinogenic types without HPV-16, and (as shown also in table 1) 50.6% for HPV-16. The 2-year risk of уCIN3 for single-type HPV infections was 3.9% for noncarcinogenic types, 7.9% for carcinogenic types without HPV-16, and 39.1% for HPV-16. All differences in risk were statistically significan ( ). Women whose infections were categorized as multiple P ! .01 carcinogenic types without HPV-16 had a nonsignificantl greater risk of уCIN3 than did women whose infections were categorized as single carcinogenic types without . However, the converse was true for infections with noncarcinogenic HPV types (1.4% vs. 3.9%).
Except for HPV-16, infections with multiple HPV types of different risk groups resulted in risks of уCIN2 and уCIN3 that were close to the risk observed for the higher of the risk types. For example, women infected with a single noncarcinogenic type and a single carcinogenic type without HPV-16 had a 2-year cumulative risk of уCIN2 of 17.3% and a 2-year cumulative risk of уCIN3 of 8.3%, which were similar to the risks of уCIN2 (18.8%) and уCIN3 (7.9%) for women infected with a single carcinogenic type without HPV-16.
By contrast, there was an apparent trend toward lower risk in women infected with HPV-16 in combination with single or multiple noncarcinogenic types. The 2-year risk of уCIN2 decreased from 50.6% to 40.0% to 36.1% among women infected with HPV-16 only, with 1 additional noncarcinogenic type, or 11 additional noncarcinogenic type, respectively. A test of trend yielded . A similar pattern of decreasing risk P p .04 (from 39.1% to 28.9% to 27.8%) was also observed using an end point of уCIN3, with a test of trend yielding . P p .07 We observed that as the overall risk of уCIN2 decreased, the ratio of CIN2 to уCIN3 increased. HPV-16 infections conferred the greatest risk of уCIN2 and the lowest ratio of CIN2 to уCIN3 (i.e., most HPV-16-positive women with уCIN2 had уCIN3). For single-type HPV-16 infections, the ratio was 0.28. By contrast, women infected with noncarcinogenic HPV types had ratios of ∼1 or greater. Women infected with multiple noncarcinogenic types had the highest ratio (6.0).
In logistic regression modeling (data not shown), age (!30 or у30 years) and referral cytological diagnosis (LSIL or ASCUS) were not confounding variables of the risks of either уCIN2 or уCIN3 associated with HPV. Having LSIL (vs. ASCUS) was significantl associated with having уCIN2 or уCIN3 (odds ratios [ORs], 1.38 and 1.40, respectively). Women у30 years of age had a significantl lower risk of уCIN2 but not of уCIN3 (ORs, 0.74 and 0.81, respectively), compared with women !30 years of age.
In table 3, we present the risk of уCIN2 diagnosed during the last 12 months of the study associated with the HPV risk status at 2 time intervals: 0 to !12 months (the year 1 period) and 12 to 24 months (the year 2 period). Women who were reclassifie in the year 2 period into a risk group that was lower or higher than the year 1 period had a decreased or an increased risk of уCIN2, respectively, compared with those who were not reclassified For example, women who were HPV negative during both time periods had a risk of 0.6% (95% CI, 0.1%-1.9%), whereas women who were negative during the year 1 period but HPV-16 positive during the year 2 period had a risk of 14.3% (95% CI, 3.0%-36.3%). Among women who were (6, 11, 26, 40, 42, 53, 54, 55, 57, 61, 62, 64, 67, (69) (70) (71) (72) (73) 81, 82, 82v, 83, 84, and 89 [CP6108] ), and the carcinogenic without HPV-16 category includes all carcinogenic HPV genotypes excluding HPV-16 (18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 NOTE. Women were assigned an HPV risk status according to the highest-risk HPV genotype detected during each time period. The noncarcinogenic category includes all noncarcinogenic HPV genotypes (6, 11, 26, 40, 42, 53, 54, 55, 57, 61, 62, 64, 67, (69) (70) (71) (72) (73) 81, 82, 82v, 83, 84, and 89 [CP6108] ), and the carcinogenic without HPV-16 category includes all carcinogenic HPV genotypes excluding HPV-16 (18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) . CI, confidence interval; PCR, polymerase chain reaction.
HPV-16 positive during the year 1 period and remained HPV-16 positive during the year 2 period, the risk of уCIN2 was 27.4% (95% CI, 19.5%-36.6%), whereas those who were HPV negative during the year 2 period had a risk of only 4.7% (95% CI, 0.6%-15.8%). Table 3 also shows the corresponding risk estimates for уCIN3. Although the numbers were small for many categories and the resulting risk estimates are imprecise, the pattern of risk was similar to that observed for уCIN2. The average duration between the diagnosis of CIN and the last PCR HPV test was 92 days for уCIN2 and 73 days for уCIN3.
DISCUSSION
We have previously reported that, in this population of mostly young women with either equivocal or mild cervical cytological abnormalities, detection of HPV-16 at entry into the study was associated with a very high risk of уCIN3 over a 2-year period [11] . Here, we report the 2-year cumulative risk of уCIN2 and уCIN3 for individual HPV types and various groupings of HPV types. We found that the recognized carcinogenic HPV types other than 16 (18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , 66, and 68) had a collective risk of уCIN3 that was approximately one-fift of that for HPV-16 (7.9% vs. 39.1%). The remaining HPV types had a collective risk of уCIN3 that was approximately one-tenth that of . Although the risks for the individual HPV types varied greatly, the limited precision of the estimates did not allow us to further distinguish the HPV types within these broad groupings.
Women in ALTS were referred for equivocal or mild cytologic abnormalities. Of note, the risk of subsequent уCIN3 would be lower in the general population, particularly among those with normal cytological f ndings. The low but nonzero subsequent risk of уCIN3 among those who tested negative for HPV at enrollment shows that HPV testing is not 100% sensitive. Nonetheless, recent screening guidelines have included repeat cytological and HPV testing every 3 years. It is expected that multiple negative HPV tests would defin an extremely low-risk group.
A recent report found a 10-year elevated risk of cervical precancer and cancer for HPV-18 that was similar in magnitude to that observed for HPV-16 [12] . The lower risk among HPV-18-positive women in the present study might be explained by the short duration of follow-up. Among the non-HPV-16 carcinogenic types, we observed the greatest risk of уCIN3 (14.8%) for HPV-31. In this study, perhaps by chance, relatively low risks of уCIN3 for HPV-56 and -59 were observed, with risks similar to those observed for the noncarcinogenic types.
Noncarcinogenic types were associated with increased risk of уCIN2, compared with the risk in women who were PCR negative. However, the risk of уCIN3 for noncarcinogenic types did not differ significantl from the risk of уCIN3 in women who were PCR negative. Thus, noncarcinogenic HPV types seem to cause CIN2 but not уCIN3, which is consistent with the rare detection of noncarcinogenic HPV types in cohort studies of longer duration and in studies of invasive cervical cancer [4, [6] [7] [8] 10] . The occasional findin of уCIN3 in women who were HPV negative might be due to false-negative results for carcinogenic HPV types or to histologic overcall.
We also observed relatively high risks for HPV-26, -82, -67, and -42; these risks were of comparable magnitude to those observed for the carcinogenic types other than HPV-16. HPV-26 and -82 have been suggested as potential carcinogenic types [7] , and, thus, our finding of relatively high risks for these types might have been expected. HPV-67, which has not been identifie in other studies as carcinogenic, resides, interestingly, in the same phylogenetic species (a-9) as the carcinogenic HPV types 16, 31, 33, 35, 52, and 58 . It is unclear whether HPV-67 is truly carcinogenic and was missed by the large case series [7] or whether it causes CIN3 but not cancer. The findin of an association between the risk of cervical precancer and HPV-42 is surprising but warrants caution, given the wide CIs for these estimated risks and possible false-negative results for coinfection with carcinogenic types. HPV-42 was not found in cancers in large surveys [7] .
In the present investigation, we also attempted to estimate the risks of combinations of HPV types. However, the low frequency of multiple infections of specifi HPV types made this impossible for all but a few combinations. Rather than look at combinations of specifi HPV types, we chose to look at combinations of types within broad risk classes. A few patterns emerged from these analyses. First, the risk classes had distinct and significantl different risk levels. Among women with a single infection, those infected with HPV-16 had the highest risk of уCIN3 (39.1%), followed by those infected with a carcinogenic type without HPV-16 (7.9%) and by those infected with a noncarcinogenic HPV type (3.9%).
Previous reports found that multiple infections with non-HPV-16 carcinogenic types significantl increased the risk of уCIN3, compared with infection with single-type non-HPV-16 carcinogenic infections [22, 23] . In the present study, we observed a similar yet nonsignifican increase in risk, compared with the risk observed for single infections of that risk class. For example, women infected with a single carcinogenic type without HPV-16 had a risk of 7.9% for уCIN3, compared with a risk of 10.9% for women infected with 2 or more carcinogenic types without HPV-16. The likely explanation for this increase in risk is that the non-HPV-16 carcinogenic types are not homogenous with respect to risk. If the risk of уCIN3 in women with multiple infections is set by the HPV type with the greatest risk, then women with multiple infections will, on average, have a greater risk of уCIN3 than will women with single infections.
A third pattern observed was that multiple infections with HPV types of different risk classes resulted in a risk that was similar to, and not significantl different from, the risk observed for the highest risk class. Women infected with a single noncarcinogenic type and a single carcinogenic type without HPV-16 had an 8.3% risk for уCIN3, which was essentially the same risk observed in women infected with a single carcinogenic type without HPV-16. Similarly, women infected with HPV-16 and either a single noncarcinogenic type or an additional single carcinogenic type had risks that were close to that observed for HPV-16 alone (29%, 39%, and 39%, respectively).
There was one interesting pattern that deviated from the above generalizations. A decreasing trend in risk was observed in the risk estimates among women infected with HPV-16 and either no, one, or multiple noncarcinogenic types. This may result from consistent antagonism between types. Previous work has suggested that antagonism between the noncarcinogenic HPV types 6 or 11 and HPV-16 results in a reduced risk for both CIN and invasive cervical cancer [24, 25] . We are currently exploring type-type interactions by use of Markov chain modeling. Another possibility is that this trend may reflec residual age confounding, given that younger HPV-16-positive women were significantl more likely to have additional carcinogenic HPV types detected than were older women ( ), who P p .0003 on average would be expected to have had their infections longer and, therefore, to be more likely to have developed precancer or cancer.
Another objective of these analyses was to investigate how a change in HPV risk status over the course of follow-up could change the risk of уCIN2 and уCIN3. By dividing the study period into 2 intervals (0 to !12 months [the year 1 period] and 12 to 24 months [the year 2 period]) and characterizing a woman's HPV risk status for each interval, we were able to show that a change in HPV risk status between the 2 relatively short periods was associated with a concordant change in the risk of уCIN2 and уCIN3.
For women who had a change in HPV risk level, the results of these analyses show that the HPV risk status during the second half of the study was much more closely related to the diagnosis of уCIN2 than was the HPV risk status 1 year earlier.
Persistence of HPV infection did, however, have an effect on risk, as the highest risk (27.4%) was observed for women who were HPV-16 positive for both years of the study. A lower, but still increased, risk was observed when a non-HPV-16 carcinogenic type persisted.
Finally, it should be stressed that the ALTS population consisted of women who were referred to 1 of 4 clinical centers in the United States with a cytologic diagnosis of ASCUS or LSIL from a community laboratory. The type-specifi prevalence of HPV and the incidence of CIN2 and CIN3 that we observed during the 2-year follow-up may not be generalizable to other populations with different characteristics.
If the present results are confi med, we will need to determine the clinical uses of HPV type-specifi testing. Given the limitations in sensitivity of colposcopy [21] , in some circumstances, persistent infection with a carcinogenic HPV type might serve as an adjunct to colposcopy and defin treatment in the absence of obvious cervical precancer. Such a change would require the development of reliable, quality-controlled HPV typing kits for general use and careful avoidance of overuse.
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